18 results about "Schizophrenia" patented technology

The invention provides a schizophrenia early recognition and risk prediction method and system based on multi-mode speech analysis, and belongs to the technical field of medical artificial intelligence. The method comprises the following steps: prospectively acquiring natural voice data of an individual in a clinical high-risk period, performing clinical follow-up visit for two years, and constructing a first Chinese schizophrenia clinical high-risk voice longitudinal data set; based on the data set, audio and text features in the voice are extracted, a layered multi-mode integrated model is constructed, semantic coherence and acoustic features are fused, and early prediction of the schizophrenia transformation risk is achieved; through feature importance analysis, key voice marks closely related to negative symptoms, thinking disorder and cognitive impairment are recognized, and non-invasive, accurate and interpretable early recognition is achieved. According to the method, the technical blank of early screening tools for schizophrenia in Chinese context is filled, and the accuracy and stability of early recognition are remarkably improved.

The invention relates to a novel compound as a 5-HT2A receptor inverse agonist, and a preparation method and a pharmaceutical composition thereof. The invention also relates to application of the compound or the pharmaceutical composition in preparation of drugs for treating 5-HT2A receptor related diseases, wherein the diseases comprise non-motor symptoms caused by Parkinson's disease, such as delusional disorder, hallusion, depression, anxiety, cognitive disorder and sleep disorder; dementia-related mental disorders; major depression; or negative symptoms of schizophrenia and the like.

The invention provides a method and device for generating information based on brain image data, and the method comprises the steps: carrying out the longitudinal brain image analysis of the brain image data, collected at multiple time points, of a target individual, carrying out regional division on the brain of the target individual at each time point and extracting morphological measurement values of each region based on a longitudinal brain image analysis result and a cortex partition map; based on the brain form norm, the deviation degree of the morphological measurement value of each region of the brain of the target individual at each time point relative to the brain form norm is determined, and the individual brain form deviation vector corresponding to the target individual at each time point is obtained; performing correlation calculation on the individual brain form deviation vector corresponding to the target individual at each time point and the statistical data of the plurality of mental diseases in the whole brain range to obtain cross-disease brain form similarity features; and inputting the cross-disease brain form similarity features into a pre-trained machine learning model, and outputting classification information about whether the target individual is a schizophrenia patient or not, and / or prediction information about clinical indexes.

The invention relates to a composition comprising a piperazine-benzazepine, a buffer and a surfactant, and uses of such compositions such as treating, preventing, and / or suppressing symptoms of schizophrenia, schizoaffective disorders, and / or Parkinson's disease. The compositions have improved parameters such as a lower variance in pH, improved stability during storage, and lower solubility of piperazine-benzazepines, resulting in piperazine-benzazepine particle formation with improved particle size and particle size distribution. The compositions are useful as therapeutic agent, for instance through parenteral administration to a subject.

The invention relates to a novel compound as a 5-HT2A receptor inverse agonist, and a preparation method and a pharmaceutical composition thereof. The invention also relates to application of the compound or the pharmaceutical composition in preparation of drugs for treating 5-HT2A receptor related diseases, wherein the diseases comprise non-motor symptoms caused by Parkinson's disease, such as delusional disorder, hallusion, depression, anxiety, cognitive disorder and sleep disorder; dementia-related mental disorders; major depression; or negative symptoms of schizophrenia and the like.

Provided are compounds of Formula I, described herein, processes for their preparation, their use as pharmaceuticals, and pharmaceutical compositions comprising them and intermediates used in their preparation. Compounds of Formula I are useful, for instance, in modulating dopamine and serotonin neurotransmission and treating disorders that may benefit from the same, such as schizophrenia and depression.

The invention relates to a novel compound as a 5-HT2A receptor inverse agonist, and a preparation method and a pharmaceutical composition thereof. The invention also relates to application of the compound or the pharmaceutical composition in preparation of drugs for treating 5-HT2A receptor related diseases, wherein the diseases comprise non-motor symptoms caused by Parkinson's disease, such as delusional disorder, hallusion, depression, anxiety, cognitive disorder and sleep disorder; dementia-related mental disorders; major depression; or negative symptoms of schizophrenia and the like.

The invention discloses a schizophrenia typing method based on delta wave band fractal dimension individual heterogeneity, and belongs to the technical field of neural information processing and mental disease auxiliary diagnosis. According to the method, firstly, innovation is achieved in the aspect of frequency band specificity analysis, feature extraction can be carried out on the schizophrenia key information processing frequency band, and disease abnormity can be captured more sensitively. And secondly, the site effect of cross-center data acquisition is effectively coordinated by introducing a ComBat method, and the modeling stability and the result reliability are improved. Thirdly, a standardized model is obtained through multi-center large sample training, individualized deviation modeling is further carried out, the abnormal degree of a single patient relative to a healthy group can be accurately described, and the limitation of traditional group mean value comparison is broken through. Afterwards, in combination with a hierarchical heterogeneity analysis method based on discriminant analysis, stage identification and potential subtype division of the disease are realized, so that the method has a refined typing capability.

The invention relates to a novel compound as a 5-HT2A receptor inverse agonist, and a preparation method and a pharmaceutical composition thereof. The invention also relates to application of the compound or the pharmaceutical composition in preparation of drugs for treating 5-HT2A receptor related diseases, wherein the diseases comprise non-motor symptoms caused by Parkinson's disease, such as delusional disorder, hallusion, depression, anxiety, cognitive disorder and sleep disorder; dementia-related mental disorders; major depression; or negative symptoms of schizophrenia and the like.

This invention discloses a submillimeter-level diffusion magnetic resonance imaging (DTI) method for extracting the radial index of cortical layered cognitive structures, relating to the field of medical image processing technology. This invention aims to address the problems of existing technologies failing to accurately quantify the directionality of cortical microstructures and neglecting the heterogeneity of cortical layering. The method includes: acquiring DTI data and performing high-fidelity preprocessing such as MP-PCA denoising, Gibbs artifact removal, and Gaussian process distortion correction; estimating the diffusion tensor and extracting the principal feature vector based on the preprocessed data; reconstructing the cortical white matter and pia mater surface using T1 images and extracting the normal vector; calculating the absolute value of the dot product of the diffusion principal feature vector and the surface normal vector to construct a radial index map; and segmenting the cortex into multiple intermediate layers based on the principle of equal volume and extracting layering parameters. Through refined high-resolution data processing and geometric modeling, this invention can accurately quantify the radial alignment integrity of cortical nerve fibers, providing highly sensitive imaging markers for cognitive disorders such as schizophrenia.

The invention discloses a method and system for constructing a schizophrenia symptom severity prediction model, and relates to the field of disease auxiliary diagnosis, and the method comprises the steps: obtaining historical electroencephalogram data of a patient, and constructing a weighted undirected connection matrix; obtaining a plurality of key graph theory indexes based on the weighted undirected connection matrix in combination with a graph theory algorithm; wherein the plurality of key graph theory indexes comprise a clustering coefficient, a path length, global efficiency and local efficiency; taking the plurality of obtained key graph theory indexes as predictive factors, and inputting the predictive factors and the dependent variable PANSS score into a constructed multiple linear regression model to determine a linear relationship between the plurality of key graph theory indexes and the dependent variable PANSS score; and obtaining a schizophrenia symptom severity prediction model for predicting the symptom severity of the schizophrenia patient according to the linear relationship between the plurality of key graph theory indexes and the PANSS score.

This invention discloses a method and system for assessing cognitive function in mental disorders based on attention mechanisms, belonging to the field of mental disorder assessment technology. The method includes: acquiring multi-channel EEG signals of subjects under an adaptive dual-task paradigm; performing time-frequency analysis to extract frequency bands and instantaneous power time-series features of the frequency bands; inputting the features into a pre-trained game-theoretic attention network to calculate the dynamic game-theoretic coupling strength between the network and oscillations, generating a game equilibrium deviation time-series sequence; extracting an imbalance threshold index and a compensation cost index from the sequence; and inputting the index into a classifier to generate a cognitive function assessment index. This invention analyzes the dynamic game-theoretic relationship between oscillations through attention mechanisms, quantifying the degree of imbalance in attention resource allocation in multi-task competitive scenarios for patients with schizophrenia. It exhibits high sensitivity and specificity, providing an objective and quantitative tool for assessing cognitive impairment in mental disorders.

The present invention relates to new uses of a 5-HT4 receptor agonist, specifically Isopropyl-3 - { 5- [ 1 -(3 - methoxypropyl) piperidin-4-yl] - [ 1,3,4] oxadiazol-2-yl } - 1 H- indazole (Compound- 1) or a pharmaceutically acceptable salts thereof, for the treatment of dementia due to menopause, senile dementia, cognitive deficits associated with schizophrenia, depression, chemotherapy-induced cognitive impairment and behavioural and psychological symptoms of dementia such as apathy / indifference, agitation, aggression, depression, anxiety, irritability / lability, dysphoria, aberrant motor behaviour, delusions, hallucinations, elation / euphoria, psychosis, disinhibition, sleep and night time behaviour disorders or appetite and eating disorders. The present invention further provides use of the said compounds in the manufacture of medicament intended for the treatment of the disorders described herein.

The application provides a cariprazine orally dissolving film composition, a preparation method and application thereof. The orally dissolving film composition comprises an active ingredient, a film forming material and a plasticizer, wherein the active ingredient is selected from a mixture of one or more of cariprazine, a pharmaceutically acceptable salt of cariprazine and an inclusion compound thereof. The orally dissolving film composition has the advantages of thin thickness, good taste, stable property, instant dissolving in the oral cavity without drinking water, fast oral absorption speed, simple process, high drug loading, good drug content uniformity, and the like. The orally dissolving film composition helps to improve the poor compliance, hiding and spitting of patients with schizophrenia, and is particularly suitable for patients with difficulty in swallowing, and has a good market prospect.

Provided is a Bifidobacterium lactis. The Bifidobacterium lactis is Bifidobacterium animalis subsp. lactis BL-11, and the preservation number of the Bifidobacterium animalis subsp. lactis BL-11 is CGMCC No. 20847. The provided Bifidobacterium animalis subsp. lactis can improve intestine metabolism disorder and normalize the composition of intestine microbiome so as to improve height, suppresses obesity, promote infant and youth physical development and mental development, and prevent and treat mental disorders, said mental disorders including anxiety, depression, attention-deficit / hyperactivity disorder, autism, schizophrenia, hepatic encephalopathy, anorexia, Tourette syndrome, and Asperger syndrome.